Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma.
暂无分享,去创建一个
[1] M. Souweidane,et al. Longitudinal Monitoring of Gd-DTPA Following Convection Enhanced Delivery in the Brainstem. , 2020, World neurosurgery.
[2] Hao Fu,et al. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF V600E by synergistically decreasing global trimethylation of H3K27 , 2020, Journal of cellular and molecular medicine.
[3] B. Himes,et al. Treatment Strategies in Diffuse Midline Gliomas With the H3K27M Mutation: The Role of Convection-Enhanced Delivery in Overcoming Anatomic Challenges , 2019, Front. Oncol..
[4] D. Reinberg,et al. Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma , 2018, Science Advances.
[5] M. Kieran,et al. The Integration of Biology Into the Treatment of Diffuse Intrinsic Pontine Glioma: A Review of the North American Clinical Trial Perspective , 2018, Front. Oncol..
[6] T. Owa,et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. , 2018, The Lancet. Oncology.
[7] K. Tobinai,et al. Targeting EZH2 with tazemetostat. , 2018, The Lancet. Oncology.
[8] S. Mueller,et al. New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model , 2018, Journal of Neuro-Oncology.
[9] M. Kaluzová,et al. Convection-enhanced delivery of cetuximab conjugated iron-oxide nanoparticles for treatment of spontaneous canine intracranial gliomas , 2018, Journal of Neuro-Oncology.
[10] Ashley R. Woodfin,et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas , 2017, Nature Medicine.
[11] B. Porse,et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas , 2017, Nature Medicine.
[12] N. Gupta,et al. Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas , 2016, Current neuropharmacology.
[13] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[14] J. Beijnen,et al. ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2‐Inhibitors , 2015, International journal of cancer.
[15] T. Wurdinger,et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[16] T. Lagerweij,et al. Convection enhanced delivery of carmustine to the murine brainstem: A feasibility study , 2014, Journal of Neuroscience Methods.
[17] C. James,et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma , 2014, Nature Medicine.
[18] Stephen Yip,et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma , 2014, Nature Genetics.
[19] D. Friedmann-Morvinski,et al. Dedifferentiation and reprogramming: origins of cancer stem cells , 2014, EMBO reports.
[20] Yonghong Xiao,et al. Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma , 2014, Molecular Cancer Therapeutics.
[21] F. Chen,et al. Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models. , 2013, Nanomedicine.
[22] B. Garcia,et al. Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma , 2013, Science.
[23] Sabine Mueller,et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. , 2013, Genes & development.
[24] R. Copeland,et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 , 2013, Proceedings of the National Academy of Sciences.
[25] M. Chamberlain,et al. Brainstem Glioma: A Review , 2013, Current Neurology and Neuroscience Reports.
[26] M. Berger,et al. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. , 2013, Neuro-oncology.
[27] K. Warren. Diffuse intrinsic pontine glioma: poised for progress , 2012, Front. Oncol..
[28] M. Prados,et al. Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment , 2012, Journal of Neuro-Oncology.
[29] W. Vandertop,et al. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. , 2012, Cancer treatment reviews.
[30] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[31] Li Ding,et al. Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.
[32] M. Prados,et al. An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing , 2012, Journal of Neuro-Oncology.
[33] S. Rosenfeld,et al. Regression of Recurrent Malignant Gliomas With Convection-Enhanced Delivery of Topotecan , 2011, Neurosurgery.
[34] C. James,et al. Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models , 2010, Journal of visualized experiments : JoVE.
[35] Francis C Szoka,et al. Barriers to carrier mediated drug and gene delivery to brain tumors. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[36] J. Kirkwood,et al. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. , 2000, The oncologist.
[37] W. Banks. Delivery of peptides to the brain: emphasis on therapeutic development. , 2008, Biopolymers.